In addition to BRAF mutant melanoma, enhanced mTORC1 activity has also been reported to associate with acquired resistance to combined inhibition of CDK4/6 and MEK in NRAS-mutant melanomas [63]. This evidence concerns the gene BRAF and melanoma.